Tiziana Life Sciences Reports Positive 6-month Data With Int

Tiziana Life Sciences Ltd. (TLSA), a clinical-stage biopharmaceutical company, announced Monday positive six-month clinical results in multiple sclerosis patients treated with intranasal Foralumab.

Related Keywords

Gabriele Cerrone , Access Program , More Such Health News , Research Of Multiple Sclerosis On , Tiziana Life Sciences , Tiziana Life Sciences Ltd , European Committee For Treatment , Modified Fatigue Impact Scale , Secondary Progressive Multiple Sclerosis , Expanded Access , European Committee , Multiple Sclerosis , Foralumab , Intranasal Foralumab ,